Adicet Bio, Inc. (ACET): who owns it and who trades it
As of Nov 16, 2026, ACET insiders reported 4 open-market sales worth $675K and 3 purchases worth $1.6M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was OrbiMed Advisors Israel II Ltd (10% owner), with $675K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Adicet Bio
From the latest filingsOverall: more selling than buying. Famous investors mostly sold. Funds mostly bought. Insiders was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ACET
56 funds and institutions reported ACET shares worth $52.8M at the end of Q2 2026, about 64% of the company. The largest holder is Ra Capital Management, L.P. with 9.7%.
Funds and institutions (13F) 64%Everyone else 36%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 932,624 | 9.72% | $8.1M | -21% |
| Orbimed Advisors LLC | 844,787 | 8.80% | $7.3M | -18% |
| Franklin Resources Inc | 626,571 | 6.53% | $5.4M | No change |
| Citadel Advisors LLC | 432,738 | 4.51% | $3.7M | +13% |
| Vanguard Capital Management LLC | 343,228 | 3.58% | $3M | +2% |
| Adage Capital Partners Gp, L.l.c. | 274,375 | 2.86% | $2.4M | No change |
| Renaissance Technologies LLC | 265,945 | 2.77% | $2.3M | +14% |
| Stonepine Capital Management, LLC | 245,518 | 2.56% | $2.1M | +11% |
| Alyeska Investment Group, L.P. | 203,799 | 2.12% | $1.8M | No change |
| Schonfeld Strategic Advisors LLC | 195,514 | 2.04% | $1.7M | New |
| Carlyle Group Inc. | 184,295 | 1.92% | $1.6M | No change |
| NEXTBio Capital Management LP | 157,827 | 1.64% | $1.4M | No change |
| Acadian Asset Management LLC | 124,832 | 1.30% | $1.1M | +6% |
| Two Sigma Investments, LP | 96,839 | 1.01% | $837K | +125% |
| Geode Capital Management, LLC | 95,634 | 1.00% | $827K | -5% |
| DAFNA Capital Management LLC | 93,812 | 0.98% | $811K | No change |
| Bridgeway Capital Management, LLC | 85,959 | 0.90% | $743K | New |
| Marshall Wace, LLP | 79,488 | 0.83% | $687K | New |
| Trexquant Investment LP | 78,002 | 0.81% | $674K | +79% |
| Jane Street Group, LLC | 70,561 | 0.74% | $610K | +90% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ACET insiders reported $1.6M of open-market purchases and $675K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Apr 8, 2026 | OrbiMed Advisors Israel II Ltd +7 | 10% owner | Sale | 32,523 | $6.29 | $205K | Form 4 |
| Apr 8, 2026 | OrbiMed Advisors Israel II Ltd +7 | 10% owner | Sale | 40,416 | $6.52 | $264K | Form 4 |
| Apr 7, 2026 | OrbiMed Advisors Israel II Ltd +7 | 10% owner | Sale | 29,319 | $6.53 | $191K | Form 4 |
| Apr 7, 2026 | OrbiMed Advisors Israel II Ltd +7 | 10% owner | Sale | 2,400 | $6.38 | $15.3K | Form 4 |
| Feb 20, 2026 | RA Capital Healthcare Fund LP +3 | 10% owner | Purchase | 74,751 | $7.27 | $543K | Form 4 |
| Feb 19, 2026 | RA Capital Healthcare Fund LP +3 | 10% owner | Purchase | 74,268 | $7.21 | $535K | Form 4 |
| Feb 18, 2026 | RA Capital Healthcare Fund LP +3 | 10% owner | Purchase | 74,577 | $7.04 | $525K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| RA Capital Healthcare Fund LP | 10% owner | $1.6M | – | Feb 20, 2026 |
| OrbiMed Advisors Israel II Ltd | 10% owner | – | $675K | Apr 8, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ACET short interest
Low short interest. 4.9% of ACET shares are sold short: about 1 share in 20. Over the last 12 reports the number of shares short went down 22%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 459,550 ACET shares were sold short, 4.9% of the shares outstanding, down 11.9% from the report before. At the average daily volume of 178,752 shares, buying them all back would take about 2.6 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 459,550 | 4.91% | -12% | 178,752 | 2.6 |
| Oct 15, 2026 | 521,883 | 5.57% | +8% | 222,595 | 2.3 |
| Sep 30, 2026 | 485,466 | 5.19% | +78% | 439,513 | 1.1 |
| Sep 15, 2026 | 271,989 | 2.91% | +8% | 131,075 | 2.1 |
| Aug 31, 2026 | 252,663 | 2.70% | -4% | 104,508 | 2.4 |
| Aug 14, 2026 | 262,357 | 2.80% | -34% | 82,757 | 3.2 |
| Jul 31, 2026 | 397,053 | 4.14% | +4% | 91,951 | 4.3 |
| Jul 15, 2026 | 383,174 | 3.99% | -24% | 89,405 | 4.3 |
| Jun 30, 2026 | 505,580 | 5.27% | +1% | 96,212 | 5.2 |
| Jun 15, 2026 | 501,254 | 5.22% | -3% | 75,738 | 6.6 |
| May 29, 2026 | 517,922 | 5.40% | -12% | 124,748 | 4.2 |
| May 15, 2026 | 587,837 | 6.13% | +6% | 103,457 | 5.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Adicet Bio company events
Adicet Bio filed 12 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Sep 28, 2026AnnouncementThe Company announced preliminary data from its Prula-cel Phase 1 study in patients with SLE with or without LN. The preliminary data, as well as additional corporate updates, are summarized below. Filing
- Sep 8, 2026AnnouncementShared information with investors. Filing
- Sep 1, 2026AnnouncementShared information with investors. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jun 18, 2026VoteReported shareholder vote results. Filing
- May 13, 2026ResultsReleased financial results. Filing
- Apr 28, 2026SharesSold new shares outside a public offering. Filing
- Mar 12, 2026ResultsReleased financial results. Filing
- Jan 7, 2026AnnouncementThe Company announced that enrollment in its prulacabtagene leucel (prula-cel, formerly ADI-001) Phase 1 program in autoimmune diseases has doubled to over 20 patients as of December 31, 2025. Filing
- Dec 29, 2025AnnouncementThe Company issued a press release announcing the Reverse Stock Split and other related information. Filing
- Dec 19, 2025VoteReported shareholder vote results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Adicet Bio financials
Famous investors that hold ACET
2 of the 50 well-known investors we track reported holding ACET in their latest 13F filing. The largest position is Ken Griffin's, worth $2M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 280,372 | $2M | 0.0% | -35% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 214,841 | $1.5M | 0.0% | -19% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ACET in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 28, 2026 | Franklin Templeton, Inc. | 13G/A | 7.7% |
| Oct 28, 2026 | Franklin Templeton, Inc. | 13G/A | 7.7% |
| Oct 23, 2026 | Zedek Daniel Clayton | 13G | 5.4% |
| Oct 23, 2026 | Zedek Daniel Clayton | 13G | 5.4% |
Questions about Adicet Bio, Inc. (ACET) stock
Who owns the most ACET stock?
The largest reported owner of Adicet Bio, Inc. (ACET) is Ra Capital Management, L.P., with 9.7% of the company. In total, 56 funds and institutions reported holding ACET at the end of Q2 2026, together about 64% of the shares. See the largest owners.
Are ACET insiders buying or selling?
In the last 12 months, ACET insiders reported 3 open-market purchases worth $1.6M and 4 sales worth $675K. The latest trade was on Apr 8, 2026. See every trade.
What is the short interest in ACET?
As of Oct 30, 2026, 459,550 ACET shares were sold short, 4.9% of the shares outstanding, down 11.9% from the report before. At the average daily volume of 178,752 shares, buying them all back would take about 2.6 trading days (days to cover). See the history.
Which famous investors hold ACET?
2 of the 50 well-known investors we track reported ACET in their latest 13F filing, including Ken Griffin, Jim Simons. The largest position is worth $2M. See all holders.
Executive pay
Adicet Bio's chief executive was paid a total of $1.5M for the year ended Dec 31, 2025, down 68% from $4.6M the year before. In the last 12 months, Adicet Bio's executives and directors bought no stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.